Abstract
Background: It was found that breast cancer susceptibility protein 1 (BRCA 1) binds to estrogen receptor alpha (ERα) and inhibits its activity by direct interaction between domains within the amino terminus of BRCA 1 and the carboxy terminus of ER alpha.
Objectives: The present work focuses to identify a new class of BRCA 1 mimetics that work differently from conventional anti-estrogens.
Methods: A novel class of hybrids having coumate and benzimidazolone scaffolds were designed to mimic BRCA 1 protein, suppressing the tumor activity of breast cancer cells. In silico molecular docking studies of the designed ligands were performed on BRCA 1 binding cavity of ER alpha.
Results: The designed hybrids which gave significant docking scores and had optimum binding interactions with key residues were selected for synthesis and in vitro assay.
Conclusion: The compounds NY1 and NY2 exhibited significant effects on suppressing MDAMB- 231 cells in the concentration of 24 μg/ml and 44 μg/ml, respectively.
Keywords: Breast cancer, scaffold, BRCA1, coumate, benzimidazolone, ERα.
Current Computer-Aided Drug Design
Title:A New Class of Coumate Benzimidazole Hybrids as BRCA 1 Mimetics Through Unconventional Binding Mode; Synthesis and Preliminary Cytotoxicity Screening
Volume: 16 Issue: 6
Author(s): Selvaraj Jubie*, Shyam Sundar, Neetu Yadav, Podila Naresh, Ashish Wadhwani and Jawahar Natarajan
Affiliation:
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Udhagamandalam JSS Academy of Higher Education & Research, Mysore,India
Keywords: Breast cancer, scaffold, BRCA1, coumate, benzimidazolone, ERα.
Abstract:
Background: It was found that breast cancer susceptibility protein 1 (BRCA 1) binds to estrogen receptor alpha (ERα) and inhibits its activity by direct interaction between domains within the amino terminus of BRCA 1 and the carboxy terminus of ER alpha.
Objectives: The present work focuses to identify a new class of BRCA 1 mimetics that work differently from conventional anti-estrogens.
Methods: A novel class of hybrids having coumate and benzimidazolone scaffolds were designed to mimic BRCA 1 protein, suppressing the tumor activity of breast cancer cells. In silico molecular docking studies of the designed ligands were performed on BRCA 1 binding cavity of ER alpha.
Results: The designed hybrids which gave significant docking scores and had optimum binding interactions with key residues were selected for synthesis and in vitro assay.
Conclusion: The compounds NY1 and NY2 exhibited significant effects on suppressing MDAMB- 231 cells in the concentration of 24 μg/ml and 44 μg/ml, respectively.
Export Options
About this article
Cite this article as:
Jubie Selvaraj *, Sundar Shyam , Yadav Neetu , Naresh Podila , Wadhwani Ashish and Natarajan Jawahar , A New Class of Coumate Benzimidazole Hybrids as BRCA 1 Mimetics Through Unconventional Binding Mode; Synthesis and Preliminary Cytotoxicity Screening, Current Computer-Aided Drug Design 2020; 16 (6) . https://dx.doi.org/10.2174/1573409916666191231102046
DOI https://dx.doi.org/10.2174/1573409916666191231102046 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
Call for Papers in Thematic Issues
Artificial Intelligence in Biomedical Research: Enhancing Data Analysis for Drug Discovery and Development
This thematic issue highlights the transformative impact of Artificial Intelligence (AI), with a particular focus on Machine Learning (ML) and Deep Learning (DL) techniques, in advancing biomedical research. As a result of these cutting-edge AI methodologies, drug discovery and development are revolutionizing data analysis. Rapid advances in artificial intelligence technologies ...read more
Computer-Aided Drug Discoveries for Emerging Diseases
Computer-aided drug design is a rapidly growing research field that continues to gain momentum, attracting increasing interest from the scientific community. This trend is largely driven by the growing utilization of machine learning and artificial intelligence in drug design and discovery. Artificial Intelligence has proven efficacy across various applications, including ...read more
Deep Learning Approaches in Bioinformatics for Computer-Aided Drug Development Targeting Brain Tumors
The integration of deep learning and bioinformatics is revolutionizing the field of computer-aided drug development, particularly in the fight against brain tumors one of the most aggressive and lethal types of cancer. Brain tumors present significant challenges due to their heterogeneity and complexity, which require novel approaches for early diagnosis ...read more
Emerging Trends in Computer-Aided Drug and Healthcare Solutions
This special issue aims to further the advancement of knowledge in drug design, healthcare innovations, and medical solutions by leveraging modern computational techniques. In recent years, computer-aided drug design has transformed the approach to medicinal chemistry, accelerating the drug discovery process and fostering innovation. The goal of this issue is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Current Signal Transduction Therapy Evidence of Probiotics in Prevention of Allergy and Asthma
Current Drug Targets - Inflammation & Allergy Pharmacogenomics: Dont Forget the Children
Current Pharmacogenomics and Personalized Medicine The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design Role of CNS Transporters in the Pharmacotherapy of HIV-1 Associated Neurological Disorders
Current Pharmaceutical Design The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets A Validated Stability-Indicating HPTLC Method for the Estimation of Capecitabine in its Tablet Dosage Form
Current Pharmaceutical Analysis Biological and Toxicological Evaluation of N-(4methyl-phenyl)-4-methylphthalimide on Bone Cancer in Mice
Anti-Cancer Agents in Medicinal Chemistry How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Prospective Clinical Applications of CRF Peptide Antagonists
Current Molecular Pharmacology Coinage Metal Complexes Against Breast Cancer
Current Medicinal Chemistry Snake Venom Peptides and Low Mass Proteins: Molecular Tools and Therapeutic Agents
Current Medicinal Chemistry Evaluation of Ligustrazine-Based Synthetic Compounds for their Antiproliferative Effects
Medicinal Chemistry Editorial [Hot Topic: Development of Drugs Interfering with Apoptosis (Executive Guest Editor: Sebastiano Cavallaro)]
Current Pharmaceutical Design Ethnopharmacological Uses, Pharmacological Activities, and Therapeutic Applications of Tectochrysin in Medicine: An Important Class of Dietary Flavonoid
Cardiovascular & Hematological Disorders-Drug Targets Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry NOB1: A Potential Biomarker or Target in Cancer
Current Drug Targets Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews